Diana Ernst, RPh

Editorial Director

Diana Ernst, RPh, is the Editorial Director for MPR, part of the Haymarket Medical Network. Since 2003, Diana has worked to provide healthcare professionals with up-to-date drug information through MPR's print and digital offerings. She is a graduate of the Ernest Mario School of Pharmacy, Rutgers University.

All articles by Diana Ernst, RPh

Pain

Gabapentin-Involved Overdose Deaths Increased Between 2019 and 2020

Diana Ernst, RPh

May 20, 2022

Researchers used data from the State Unintentional Drug Overdose Reporting System in order to assess trends in gabapentin-involved overdose deaths.

Migraine and Headache

FDA Delays Decision on Meloxicam/Rizatriptan Combination for Acute Migraine

Diana Ernst, RPh

May 16, 2022

AXS-07 is an oral agent that consists of meloxicam, a COX-2 preferential nonsteroidal anti-inflammatory drug, and rizatriptan, a 5-HT1B/1D agonist.

Neurodegenerative Diseases

FDA Panel Votes on Fixed-Dose Combination Therapy for ALS

Diana Ernst, RPh

April 15, 2022

AMX0035 is an oral, fixed-dose coformulation of sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine.

General Medicine

Oral Antiviral Treatments for COVID-19: Molnupiravir and Paxlovid

Diana Ernst, RPh

January 25, 2022

Concise drug information for molnupiravir and Paxlovid; the FDA granted Emergency Use to both oral antiviral therapies.

Neuropathy

AAN: Painful Diabetic Neuropathy Treatment Guidelines Updated

Diana Ernst, RPh

January 11, 2022

Several pharmacotherapies have been shown to reduce pain in patients with painful diabetic neuropathy.

Neurodegenerative Diseases

Fixed-Dose Combo Therapy for Amyotrophic Lateral Sclerosis Gets Priority Review

Diana Ernst, RPh

January 10, 2022

AMX0035 is an oral, fixed-dose coformulation of sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine.

General Medicine

Early Data Suggest Potential Benefit of Heterologous Boosting for COVID-19

Diana Ernst, RPh

December 10, 2021

The independent study conducted by Dan Barouch, MD, PhD, et al of Beth Israel Deaconess Medical Center included a subset of participants from the COV2008 study.